86 - Clinical Controversies

10/3/2019

3:15 PM - 4:30 PM

Room: Walter E. Washington Convention Center, Ballroom ABC (3rd Floor)

MOC Credit: Maximum of 1.25 hours of MOC Credit
CME Credit: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE Credit: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: 0221-9999-19-349-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

list and describe the risks and benefits of providing oral therapy for uncomplicated Staphylococcus aureus bacteremia
identify the rationale for not selecting fluoroquinolones as first-line therapy

Presentations:

3:15 PM - 4:30 PM
860 - Oral Therapy For Uncomplicated Staph aureus Bacteremia
Vance G. Fowler, Jr., MD, MHS – Duke University
3:15 PM - 4:30 PM
859 - Oral Therapy For Uncomplicated Staph aureus Bacteremia
Patty Wright, MD – Vanderbilt University Medical Center
3:15 PM - 4:30 PM
857 - Should Fluoroquinolones Be Abandoned As First Line Therapy For Anything?
Jennifer Pisano, MD – University of Chicago
3:15 PM - 4:30 PM
858 - Should Fluoroquinolones Be Abandoned As First Line Therapy For Anything?
Matthew Scarborough, MRCP, FRCPath, PhD – Oxford University Hospitals, UK

Debate Style Speaker(s)

VF

Vance Fowler, Jr., MD, MHS

Professor of Medicine
Duke University
Durham, North Carolina

Disclosure: Green Cross, Cubist, Cerexa, Durata, Theravance
Debiopharm: Educational fees, Other Financial or Material Support
MedImmune, Cerexa/Forest/Actavis/Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Cubist/Merck
Medical Biosurfaces
Locus
Affinergy
Contrafect
Karius
Genentech, Regeneron, Basilea: Research Grant
Pfizer, Novartis, Galderma, Novadigm, Durata, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., Cerexa, Tetraphase, Trius, MedImmune, Bayer, Theravance, Cubist, Basilea, Affinergy, Janssen, xBiotech, Contrafect, Regeneron, Basilea, Destiny.: Consultant
UpToDate: Other Financial or Material Support, Royalties
Jennifer Pisano, MD

Assistant Professor
University of Chicago
Chicago, IL

Disclosure: Nothing to disclose
Matthew Scarborough, MRCP, FRCPath, PhD

Consultant physician in Clinical Infection
Oxford University Hospitals, UK
Headington, Oxford, United Kingdom

Disclosure: Nothing to disclose
Patty Wright, MD

Professor
Vanderbilt University Medical Center
Nashville, TN

Disclosure: Cumberland Pharmaceuticals: Advisory Board

Interactive Moderator(s)

Patrick Joseph, MD

Associate Clinical Professor
University of California, San Francisco
San Ramon, CA

Disclosure: Nothing to disclose
Susan Bleasdale, MD

Associate Professor, Medical Director IC&ASP
University of Illinois
Chicago, IL

Disclosure: Nothing to disclose